Skip to main content

NASDAQ:AXNX - Axonics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $65.75
  • Forecasted Upside: 21.69 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$54.03
▲ +2.64 (5.14%)
1 month | 3 months | 12 months
Get New Axonics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXNX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$65.75
▲ +21.69% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Axonics in the last 3 months. The average price target is $65.75, with a high forecast of $77.00 and a low forecast of $57.00. The average price target represents a 21.69% upside from the last price of $54.03.

Buy

The current consensus among 7 polled investment analysts is to buy stock in Axonics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2021Needham & Company LLCBoost Price TargetBuy$71.00 ➝ $72.00Medium
i
5/13/2021Morgan StanleyBoost Price TargetOverweight$58.00 ➝ $62.00Medium
i
5/7/2021Needham & Company LLCBoost Price TargetBuy$71.00 ➝ $72.00High
i
5/7/2021Morgan StanleyBoost Price TargetOverweight$58.00 ➝ $62.00High
i
5/7/2021Piper SandlerReiterated RatingOverweight$70.00 ➝ $75.00High
i
5/3/2021Piper SandlerBoost Price TargetOverweight$70.00 ➝ $75.00Low
i
3/30/2021Needham & Company LLCBoost Price TargetBuy$66.00 ➝ $71.00Medium
i
3/24/2021Needham & Company LLCBoost Price TargetPositive ➝ Buy$66.00 ➝ $71.00High
i
3/12/2021Piper SandlerBoost Price TargetPositive ➝ Overweight$64.00 ➝ $68.00Low
i
3/4/2021Needham & Company LLCBoost Price TargetBuy$62.00 ➝ $66.00Low
i
2/26/2021Needham & Company LLCBoost Price TargetBuy$62.00 ➝ $66.00High
i
1/26/2021Robert W. BairdBoost Price TargetOutperform$58.00 ➝ $65.00High
i
1/26/2021Piper SandlerBoost Price TargetOverweight$57.00 ➝ $64.00High
i
1/7/2021Morgan StanleyBoost Price TargetOverweight$53.00 ➝ $58.00N/A
i
11/5/2020TruistBoost Price Target$50.00 ➝ $58.00High
i
11/5/2020Wells Fargo & CompanyBoost Price Target$51.00 ➝ $57.00High
i
11/5/2020Robert W. BairdBoost Price TargetBuy ➝ Outperform$52.00 ➝ $58.00High
i
11/5/2020Piper SandlerBoost Price TargetOverweight$50.00 ➝ $57.00High
i
Rating by Adam Maeder at Piper Sandler
11/5/2020Needham & Company LLCBoost Price TargetBuy$57.00 ➝ $62.00High
i
Rating by Michael Matson at Needham & Company LLC
10/23/2020GuggenheimInitiated CoverageBuy$77.00High
i
10/12/2020SVB LeerinkBoost Price TargetOutperform$59.00 ➝ $60.00Medium
i
9/2/2020Robert W. BairdInitiated CoverageOutperform$52.00High
i
8/10/2020Morgan StanleyBoost Price TargetOverweight$42.00 ➝ $53.00Low
i
8/7/2020SVB LeerinkBoost Price TargetOutperform$48.00 ➝ $59.00Medium
i
8/3/2020Needham & Company LLCReiterated RatingBuy$48.00 ➝ $57.00Low
i
Rating by Michael Matson at Needham & Company LLC
7/27/2020Piper SandlerReiterated RatingBuy$45.00High
i
Rating by Adam Maeder at Piper Sandler
7/22/2020SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $48.00Low
i
7/13/2020Needham & Company LLCReiterated RatingBuy$48.00High
i
6/5/2020Wells Fargo & CompanyBoost Price TargetOverweight$40.00 ➝ $42.00High
i
5/6/2020Morgan StanleyBoost Price TargetOverweight$36.00 ➝ $42.00High
i
4/21/2020Piper SandlerLower Price TargetOverweight$48.00 ➝ $44.00High
i
4/8/2020Wells Fargo & CompanyLower Price TargetOverweight$47.00 ➝ $35.00Medium
i
3/27/2020Morgan StanleyLower Price TargetBuy$42.00 ➝ $36.00Low
i
3/9/2020Needham & Company LLCReiterated RatingBuy$48.00High
i
3/5/2020SunTrust BanksBoost Price TargetIn-Line ➝ Buy$38.00 ➝ $48.00High
i
3/5/2020Piper SandlerReiterated RatingOverweight$44.00 ➝ $48.00High
i
1/7/2020SunTrust BanksInitiated CoverageBuy$38.00Low
i
12/6/2019Wells Fargo & CompanyReiterated RatingBuyLow
i
11/5/2019Needham & Company LLCReiterated RatingBuy$48.00Low
i
11/1/2019Piper Jaffray CompaniesInitiated CoverageOverweight$39.00 ➝ $39.00High
i
10/23/2019Needham & Company LLCReiterated RatingBuyLow
i
10/21/2019BarclaysInitiated CoverageOverweight$43.00Low
i
9/17/2019SVB LeerinkInitiated CoverageOutperform$45.00High
i
Rating by D. Antalffy at SVB Leerink LLC
9/10/2019Bank of AmericaBoost Price TargetBuy$35.00 ➝ $40.00High
i
9/3/2019Needham & Company LLCInitiated CoverageBuy$43.00 ➝ $43.00Low
i
7/2/2019Wells Fargo & CompanyBoost Price TargetOutperform$35.00 ➝ $47.00Low
i
6/13/2019Bank of AmericaBoost Price TargetBuy$30.00 ➝ $35.00High
i
5/10/2019SunTrust BanksBoost Price TargetBuy$33.00High
i
3/5/2019SunTrust BanksBoost Price TargetPositive ➝ Buy$26.00High
i
12/2/2018Morgan StanleyInitiated CoverageOverweight$21.00 ➝ $14.92High
i
11/26/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$20.00Medium
i
11/26/2018Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$22.00Medium
i
11/26/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$21.00Medium
i
11/26/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$23.00Medium
i
(Data available from 5/16/2016 forward)
Axonics logo
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, France, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $54.03
$49.95
$54.26

50 Day Range

MA: $58.98
$51.39
$63.26

52 Week Range

Now: $54.03
$32.15
$64.36

Volume

769,323 shs

Average Volume

568,680 shs

Market Capitalization

$2.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Axonics?

The following Wall Street sell-side analysts have issued research reports on Axonics in the last year: Guggenheim, Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, SVB Leerink LLC, Truist, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for AXNX.

What is the current price target for Axonics?

8 Wall Street analysts have set twelve-month price targets for Axonics in the last year. Their average twelve-month price target is $65.75, suggesting a possible upside of 21.7%. Guggenheim has the highest price target set, predicting AXNX will reach $77.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $57.00 for Axonics in the next year.
View the latest price targets for AXNX.

What is the current consensus analyst rating for Axonics?

Axonics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AXNX will outperform the market and that investors should add to their positions of Axonics.
View the latest ratings for AXNX.

What other companies compete with Axonics?

How do I contact Axonics' investor relations team?

Axonics' physical mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company's listed phone number is 949-396-6322 and its investor relations email address is [email protected] The official website for Axonics is www.axonics.com.